Results for: Gyn

12 Trials Avaliable

  • GYN 101

    A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 ' platinum resistant disease and are PARP inhibitor na've; Cohort 2 ' had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.

  • GYN 102

  • GYN 103

  • GYN 104

  • GYN 106

    A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

  • GYN 107

    A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary EfficacyStudy of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients withAdvanced Epithelial Ovarian Cancer (Including Fallopian Tube or PrimaryPeritoneal Cancers)

  • GYN 81

    A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer

  • GYN 84

    A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • GYN 88

    A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolR?) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

  • GYN 92

    MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced HighGrade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

  • GYN 93

    Phase 1 Dose Escalation Study of the Agonist RedirectedCheckpoint, SL-172154 (SIRPa-Fc-CD40L) Administered Intravenously inSubjects with Ovarian Cancer

  • GYN 99

    An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)